Trials / Not Yet Recruiting
Not Yet RecruitingNCT05060705
"Efesovir" (FS-1) for COVID-19, Phase 2
Randomized Controlled Open Study of Safety and Preliminary Efficiency of the Drug "Efesovir" (Oral Solution) for Coronavirus Infection (COVID-19)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- Sponsor
- Scientific Center for Anti-infectious Drugs, Kazakhstan · Industry
- Sex
- All
- Age
- 18 Years – 59 Years
- Healthy volunteers
- Not accepted
Summary
Study of the efficacy and safety of the new drug "Efesovir" in comparison with the drug "Remdesivir" in the treatment of patients hospitalized with COVID-19. The hypothesis of clinical study is the clinical efficacy of new drug "Efesovir" is 10% to 30% higher than of "Remdesivir".
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Efesovir | Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease. |
Timeline
- Start date
- 2025-12-01
- Primary completion
- 2026-04-01
- Completion
- 2026-11-01
- First posted
- 2021-09-29
- Last updated
- 2024-04-17
Locations
1 site across 1 country: Kazakhstan
Source: ClinicalTrials.gov record NCT05060705. Inclusion in this directory is not an endorsement.